Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.58 |
| ▸ | RNASEL | Q05823 | 9/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19147165 | 0.95 | DTYMK (0.55) | DTYMKRNASEL | |
| SCHEMBL19152966 | 0.94 | DTYMK (0.57) | DTYMKRNASEL | |
| SCHEMBL19147041 | 0.89 | DTYMK (0.59) | DTYMKRNASEL | |
| SCHEMBL19152085 | 0.88 | DTYMK (0.54) | DTYMKRNASEL | |
| SCHEMBL19147022 | 0.86 | DTYMK (0.62) | DTYMKRNASEL | |
| SCHEMBL19147053 | 0.81 | DTYMK (0.58) | DTYMKRNASEL | |
| SCHEMBL24325350 | 0.81 | DTYMK (0.58) | DTYMKRNASEL | |
| SCHEMBL19129897 | 0.81 | RNASEL (0.47) | RNASEL | |
| SCHEMBL29306731 | 0.80 | DTYMK (0.69) | DTYMKRNASEL | |
| SCHEMBL25912829 | 0.80 | DTYMK (0.69) | DTYMKRNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | DTYMK 156/4885RNASEL 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.